Table 1.
Marketed CAR-T cell therapies
| Name | Target | Manufacturer | Country | Disease | ORR | CRR | Adverse event of any grade (grade ≥ 3) | CRS of any grade (grade ≥ 3) | NT of any grade (grade ≥ 3) | Approved time | PMID |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Kymriah (Tisagenlecleucel) | CD19 | Novartis pharma | America | B-ALL | 81% | 60% | 100% (88%) | 77% (46%) | 40% (13%) | 2017 Aug | 29385370 |
| LBCL (3rd-line treatment) | 52% | 40% | 100% (89%) | 58% (22%) | 26% (15%) | 2018 May | 30501490 | ||||
| FL (3rd-line treatment) | 86% | 69% | 99% (78%) | 49% (0%) | 37% (3%) | 2022 May | 34921238 | ||||
| Yescarta (Axicabtagene ciloleucel) | CD19 | Kite pharma | America | LBCL (3rd-line treatment) | 82% | 58% | 100% (95%) | 93% (13%) | 64% (28%) | 2017 Oct | 29226797 |
| FL (3rd-line treatment) | 92% | 74% | 99% (86%) | 82% (7%) | 59% (19%) | 2021 Mar | 34895487 | ||||
| LBCL (2nd-line treatment) | 83% | 65% | 100% (91%) | 92% (6%) | 60% (21%) | 2022 Apr | 34891224 | ||||
| Tecartus (Brexucabtagene autoleucel) | CD19 | Kite pharma | America | MCL | 93% | 67% | 100% (98%) | 91% (15%) | 63% (31%) | 2020 Jul | 32242358 |
| B-ALL | 71% | 56% | 100% (95%) | 89% (24%) | 60% (25%) | 2021 Oct | 34097852 | ||||
| Breyanzi (Lisocabtagene maraleucel) | CD19 | Juno therapeutics/bristol myers squibb | America | LBCL (3rd-line treatment) | 73% | 53% | 99% (79%) | 42% (2%) | 30% (10%) | 2021 Feb | 32888407 |
| LBCL (2nd-line treatment) | 86% | 66% | N.A. (92%) | 49% (1%) | 12% (4%) | 2022 Jun | 35717989 | ||||
| Abecma (Idecabtagene vicleucel) | BCMA | Bristol myers squibb/bluebird bio | America | MM (5th-line treatment) | 73% | 33% | 100% (99%) | 84% (5%) | 18% (3%) | 2021 Mar | 33626253 |
| Carteyva (Relmacabtagene autoleucel) | CD19 | JW therapeutics | China | LBCL (3rd-line treatment) | 78% | 53% | 92% (56%) | 48% (5%) | 20% (3%) | 2021 Sep | 36842849 |
| Carvykti (Ciltacabtagene autoleucel) | BCMA | Janssen biotech/legend biotech | America | MM (5th-line treatment) | 97% | 67% | 100% (94%) | 95% (4%) | 21% (9%) | 2022 Feb | 34175021 |
| CT103A (Equecabtagene autoleucel) | BCMA | IASO biotherapeutics/innovent biologics | China | MM (4th-line treatment) | 96% | 74% | N.A. (N.A.) | 93% (1%) | 2% (0%) | 2023 Jun | 33512480, 35314675 |